Market revenue in 2023 | USD 25.8 million |
Market revenue in 2030 | USD 54.0 million |
Growth rate | 11.1% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.08% in 2023. Horizon Databook has segmented the Norway head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Similar to other European countries, Norway witnesses a high demand for head and neck cancer therapeutics due to the country's high prevalence of the target diseases. According to the IARC, the number of new oropharynx cancer cases is estimated to increase from 185 cases in 2020 to 212 cases by 2030.
The funding by organizations for boosting head and neck cancer research also allows the market to expand. In April 2023, Norwegian researchers collaborated with partners in Tanzania on a head and neck cancer research project.
This collaboration is a part of the Establishment of Joint Research-Based Education in Dentistry in Norway and East Africa project. It is supported by the Norwegian Agency for International Cooperation and Quality Enhancement in Higher Education (DIKU) under the NORPART program.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Norway head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account